Oncolytic Virotherapy
Oncolytic virotherapy is a form of cancer treatment that uses viruses that selectively infect and kill cancer cells, while sparing normal cells. The viruses, known as oncolytic viruses (OVs), can be naturally occurring or genetically engineered.
Mechanism of Action
- Direct Oncolysis: Viruses replicate within tumor cells, causing cell lysis and release of progeny virions.
- Immune Activation: Tumor cell death releases tumor-associated antigens, stimulating a systemic anti-tumor immune response.
- Vascular Disruption: Some OVs target tumor vasculature, cutting off blood supply to the tumor.
Clinical Applications
- Recurrent Breast Cancer: Investigated for cases resistant to standard therapies.
- Melanoma: Talimogene laherparepvec (T-VEC) is an FDA-approved oncolytic virus for melanoma.
- Solid Tumors: Ongoing trials for glioblastoma, pancreatic, and liver cancers.
Notable Case: Dr. Beata Halassy
Dr. Beata Halassy, a Croatian virologist, utilized self-administered oncolytic virotherapy after her aggressive breast cancer recurred multiple times despite surgery and four harsh rounds of chemotherapy. Her case highlights the potential for patient-led experimental approaches in recurrent cancer scenarios.
- Source: Self-Administered Oncolytic Virotherapy in Recurrent Breast Cancer: Dr. Halassy’s Case
- Video Reference: Self-Administered Oncolytic Virotherapy in Recurrent Breast Cancer: Dr. Halassy’s Case
Risks and Challenges
- Immune Clearance: Pre-existing immunity to the viral vector may reduce efficacy.
- Toxicity: Systemic inflammation or cytokine release syndrome.
- Regulatory Hurdles: Complex approval processes for genetically modified viruses.
See Also
- Immunotherapy
- Gene Therapy
- Cancer Vaccines
- Talimogene laherparepvec